#Class Action #Regeneron Pharmaceuticals #trial failure

Regeneron Pharmaceuticals Faces Securities Class Action

Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) finds itself in the eye of a storm as it faces a securities class action lawsuit stemming from disconcerting disclosures regarding a Phase 3 clinical trial of its therapy designed to treat melanoma. The company's announcement of the trial's failure led to a significant decline in stock value, wiping out approximately $11 billion from its market capitalization. This drastic financial fallout has catalyzed legal action aimed at protecting investors who acquired shares between August 1, 2025, and May 15, 2026.

The lawsuit, spearheaded by the national shareholder rights firm Hagens Berman, alleges that Regeneron misled investors by maintaining an overly optimistic outlook on the efficacy of its trial for a combination therapy known as Fianlimab and Libtayo. This lawsuit targets not only the company but also its management for failing to disclose critical information about the trial's protocol and the actual performance of the therapy in achieving its primary endpoint—progression-free survival (PFS).

Throughout the class period, Regeneron's executives reassured investors, implying that the combination therapy would perform as anticipated, even announcing that the trial was yielding favorable results. However, the underlying reality painted a different picture: the treatment's performance was not meeting the expectations set forth by the company. The trial's primary endpoint was purportedly based on statistical assumptions that the complaint argues were fundamentally flawed. As such, it became increasingly clear that the active treatment arm lacked the necessary differentiation over existing therapies and was unlikely to reach the desired outcomes.

The deception escalated when, on April 29, 2026, Regeneron revealed modifications to the trial protocol, indicating that the primary analysis would now consider all study participants enrolled with a minimum follow-up of six months. This admission raised flags among industry analysts, with one questioning whether the changes were made because the anticipated PFS advantages were insufficient to demonstrate statistical significance.

In the subsequent revelations, Regeneron disclosed that it had altered the trial protocol in response to